Larimar will present three posters during the conference, one of which will also be presented as an oral presentation. The poster presentations are as follows: Effect of nomlabofusp administration on ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...

PPS said "posters advocating for specific positions on political positions are not student centered." It's unclear if a ...

At Beijing's largest antiques market, Panjiayuan, among the Mao statues, posters and second-hand books are prominent signs ...

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary b ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

BEIJING - At Beijing's largest antiques market, Panjiayuan, among the Mao statues, posters and second-hand books are ...

Overall, the Company believes that the results to date from the TAMARACK study indicate antitumor activity associated with vobra duo in mCRPC as demonstrated by the protocol-specified primary endpoint ...

The data will be presented in an oral poster presentation and three ... financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier ...